Lisata Therapeutics, Inc. (LSTA) Research

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

Market snapshot

Symbol
LSTA
Price
$3.52
Day change
0.00%
Market cap
$32.1M
P/E ratio
-1.94x
52-week range
1.81-5.07
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

    Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.

  • Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

    Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value...

Peer companies

  • CASI Pharmaceuticals, Inc. (CASI)
  • CollPlant Biotechnologies Ltd. (CLGN)
  • Clearside Biomedical, Inc. (CLSD)
  • Enlivex Therapeutics Ltd. (ENLV)
  • Klotho Neurosciences, Inc. (KLTO)
  • MetaVia Inc. (MTVA)
  • NuCana plc (NCNA)
  • Passage Bio, Inc. (PASG)

Recent insider activity

  • Mazzo David J — A-Award (81000 shares) on 2026-01-09
  • Mazzo David J — F-InKind (10503 shares) on 2026-01-09
  • Mazzo David J — F-InKind (10515 shares) on 2026-01-09
  • Mazzo David J — F-InKind (12224 shares) on 2026-01-09
  • Mazzo David J — F-InKind (7854 shares) on 2026-01-09

Open Lisata Therapeutics, Inc. (LSTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.